Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels

Figures & data

Table I. Tumor response [% (SE)].

Tumors	n	CR	PR	No response	OR
Th− Seq-BNCT*
Total	92	68 (5)	23 (5)	9 (3)	91 (3)
Large (> 100 mm^3)	8	25 (15)	63 (17)	12 (17)	88 (11)
Medium (10–100 mm^3)	21	52 (11)	43 (11)	5 (6)	95 (5)
Small (< 10 mm^3)	63	79 (5)	11 (4)	10 (4)	90 (4)
Th+ Seq-BNCT
Total	78	87 (4)	13 (4)	0	100
Large (> 100 mm^3)	3	0	100	0	100
Medium (10–100 mm^3)	20	75 (10)	25 (10)	0	100
Small (< 10 mm^3)	55	96 (3)	4 (3)	0	100
Th− Seq-BO*
Total	31	0	6 (4)	94 (4)	6 (4)
Large (> 100 mm^3)	1	0	0	100	0
Medium (10–100 mm^3)	4	0	25 (22)	75 (22)	25 (22)
Small (< 10 mm^3)	26	0	4 (4)	96 (4)	4 (4)
Th+ Seq-BO
Total	33	0	6 (4)	94 (4)	6 (4)
Large (> 100 mm^3)	0	0	0	0	0
Medium (10–100 mm^3)	8	0	13 (12)	88 (11)	13 (12)
Small (< 10 mm^3)	25	0	4 (4)	96 (4)	4 (4)

*Data reported in Molinari et al., 2011.

Figure 1. Light microscopy images (20×). Histological sections (10 μm) of a pouch treated with Th+ Seq-BNCT, 28 days post-treatment (hematoxylin-eosin stain). (A) Normal-looking epithelium, with areas of hyperplasia; (B) Area with abundant fibrous hyaline tissue, with a scar-like appearance, underlying the epithelium.

Figure 2. Light microscopy images of cryostat sections (30 μm) of tumor stained with hematoxylin-eosin and the corresponding neutron autoradiography images (10×). P = parenchyma, S = stroma.

Figure 3. Light microscopy images of cryostat sections (30 μm) stained with hematoxylin-eosin and the corresponding neutron autoradiography images (10×). PT = premalignant tissue, NT = normal tissue.